Shilpa Medicare receives 8 observations from USFDA for Unit 4 at Jadcherla
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The company will soon be launching a new portfolio of products in this segment
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
The partnership will enable rapid and reliable product delivery
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
Subscribe To Our Newsletter & Stay Updated